Analyst Reco. Korro Bio, Inc.

Equities

KRRO

US5009461089

Delayed Nasdaq Other stock markets 10:09:17 2024-06-10 am EDT			5-day change	1st Jan Change
46.99 ^USD	+1.27%		-7.85%	-2.95%

May. 15	HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	MT
May. 14	Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	May. 15	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept	Mar. 28	MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk	Mar. 27	MT
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120	Feb. 27	MT
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target	Dec. 04	MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein	Nov. 29	MT
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target	Nov. 10	MT
Baird Downgrades Frequency Therapeutics to Neutral From Outperform	23-09-26	MT
Chardan Downgrades Frequency Therapeutics to Neutral From Buy	23-02-15	MT
Baird Adjusts Frequency Therapeutics Price Target to $4 From $10, Maintains Outperform Rating	23-02-14	MT
Oppenheimer Downgrades Frequency Therapeutics to Perform From Outperform, Removes $8 Price Target	23-02-14	MT
Cowen Downgrades Frequency Therapeutics to Market Perform From Outperform	23-02-13	MT
Chardan Initiates Frequency Therapeutics With Buy Rating, $7 Price Target	22-12-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Korro Bio, Inc.

Equities

KRRO

US5009461089

Analyst Reco.

Filters